Traws Pharma, Inc. (TRAW)

NASDAQ: TRAW · IEX Real-Time Price · USD
0.420
+0.022 (5.53%)
Jul 15, 2024, 12:12 PM EDT - Market open
5.53%
Market Cap 10.75M
Revenue (ttm) 226,000
Net Income (ttm) -18.16M
Shares Out 25.31M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 168,497
Open 0.400
Previous Close 0.398
Day's Range 0.400 - 0.439
52-Week Range 0.330 - 1.150
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Aug 16, 2024

About TRAW

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-k... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 25, 2013
Employees 17
Stock Exchange NASDAQ
Ticker Symbol TRAW
Full Company Profile

Financial Performance

In 2023, Traws Pharma's revenue was $226,000, a change of 0.00% compared to the previous year's $226,000. Losses were -$18.95 million, -0.08% less than in 2022.

Financial numbers in USD Financial Statements

News

Traws Pharma Announces New Employee Inducement Grants

NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection ...

3 months ago - GlobeNewsWire

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

NEWTOWN, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and develo...

4 months ago - GlobeNewsWire

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compa...

7 months ago - GlobeNewsWire

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developin...

8 months ago - GlobeNewsWire

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the registrational ...

8 months ago - GlobeNewsWire

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

NEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and develop...

8 months ago - GlobeNewsWire

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models

9 months ago - GlobeNewsWire

Onconova Expands Leadership Team with Two Key Appointments

Dr. Victor Moyo named Chief Medical Officer Meena Arora joins as Vice President Global Medical Affairs and R&D NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX...

9 months ago - GlobeNewsWire

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023 Additional studies support broad potential, especially in cyclin-dependent cancers

9 months ago - GlobeNewsWire

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developi...

10 months ago - GlobeNewsWire

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

NEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developi...

11 months ago - GlobeNewsWire

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib, the current standard-of-care Narazaciclib ...

1 year ago - GlobeNewsWire

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa Trial in Progr...

1 year ago - GlobeNewsWire

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

NEWTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) --   Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel produc...

1 year ago - GlobeNewsWire

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

Showcase to feature presentations by key opinion leaders Drs. Gaël Roué and Bhavana Pothuri Showcase to take place on May 18, 2023 at 11:00 a.m.

1 year ago - GlobeNewsWire

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

Company to host conference call and webcast at 4:30 p.m. ET on Monday, May 15, 2023 Company to host conference call and webcast at 4:30 p.m. ET on Monday, May 15, 2023

1 year ago - GlobeNewsWire

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder

NEWTOWN, Pa., April 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and develo...

1 year ago - GlobeNewsWire

Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib

Collaboration builds off clinical data demonstrating rigosertib's activity against PLK1 and may inform a precision medicine approach towards rigosertib's evaluation in new indications

1 year ago - GlobeNewsWire

Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

Conference call and live webcast at 4:30 p.m. ET today Conference call and live webcast at 4:30 p.m. ET today

1 year ago - GlobeNewsWire

Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting

NEWTOWN, Pa., March 15, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel produc...

1 year ago - GlobeNewsWire

Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

Company to host conference call and webcast at 4:30 p.m. ET on Thursday, March 16, 2023 Company to host conference call and webcast at 4:30 p.m. ET on Thursday, March 16, 2023

1 year ago - GlobeNewsWire

Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib's Mechanisms of Action at the AACR Targeting RAS Conference

Data suggest rigosertib stimulates an anti-cancer immune response via NLRP3 activation, providing mechanistic support for clinical trials of rigosertib-checkpoint inhibitor combinations

1 year ago - GlobeNewsWire

Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib's Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

Two of two evaluable participants in an ongoing investigator-sponsored program of rigosertib in RDEB-associated squamous cell carcinoma (SCC) have achieved a complete response of all cancerous skin le...

1 year ago - GlobeNewsWire

Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors

NEWTOWN, Pa., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel product...

1 year ago - GlobeNewsWire

Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference

NEWTOWN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients...

1 year ago - GlobeNewsWire